Burden of Chronic Kidney Disease in China, 1990-2021: Findings from the 2021 Global Burden of Disease Study
This week, new biomedical research published on June 9, 2026, includes findings from the 2021 Global Burden of Disease Study on the burden of Chronic Kidney Disease in China from 1990-2021, appearing in medRxiv Epidemiology & Public Health. bioRxiv Cancer & Immunology Translation published research on the reconstruction of septin higher-order nano-size structures in ovarian cancer cells, uncovering susceptibility to the septin-targeting small molecule UR214-9. The same day, bioRxiv Protein Structure & Drug Discovery featured two studies: one on the discovery of ILT3 (LILRB4) small molecule inhibitors by affinity selection-mass spectrometry, revealing the druggability of a neuroimmune checkpoint in Alzheimer's Disease, and another on targeting the myeloid immune checkpoint ILT3 (LILRB4) with small molecules to reprogram suppressive tumor immunity. Additionally, on June 8, 2026, bioRxiv Cancer & Immunology Translation published research on how the loss of Arginase 2 promotes lung metastasis in immune-competent hosts via Nitric Oxide Synthase 2-Dependent Th17 Response. Synthesized from 344 manifests produced by 27 monitored biomedical research sources in the last 7 days, including bioRxiv, medRxiv, HHS.
Answer updated Jun 11, 2026 00:00 UTC · rebuilt twice daily from the rolling 168-hour window
Burden of Chronic Kidney Disease in China, 1990-2021: Findings from the 2021 Global Burden of Disease Study
Reconstruction of septin higher-order nano-size structures in ovarian cancer cells uncover susceptibility to the septin-targeting small molecule UR214-9
Discovery of ILT3 (LILRB4) Small Molecule Inhibitors by Affinity Se-lection-Mass Spectrometry Reveals Druggability of a Neuroimmune Checkpoint in Alzheimers Disease
Loss of Arginase 2 Promotes Lung Metastasis in immune-competent hosts via Nitric Oxide Synthase 2-Dependent Th17 Response
Targeting the Myeloid Immune Checkpoint ILT3 (LILRB4) with Small Molecules Enables Reprogramming of Suppressive Tumor Immunity